dopamiinin

Dopamine is a neurotransmitter and catecholamine that plays a central role in the brain and body. In Finnish, the substance is called dopamiini, with the genitive form dopamiinin used in sentence structure. It is synthesized from the amino acid tyrosine through a pathway involving tyrosine hydroxylase and L-aromatic amino acid decarboxylase to produce dopamine. In the brain, dopamine is broken down by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) and is cleared from synapses by the dopamine transporter (DAT). Dopamine itself does not cross the blood-brain barrier; its precursor L-DOPA is used clinically for brain delivery.

Neuroanatomically, dopaminergic neurons project to several important pathways. The nigrostriatal pathway (substantia nigra to striatum) regulates movement. The mesolimbic and mesocortical pathways (ventral tegmental area to limbic structures and cortex) are involved in reward, motivation, and cognition. The tuberoinfundibular pathway influences prolactin release from the pituitary. Dopamine acts through D1-like receptors (D1 and D5) and D2-like receptors (D2, D3, D4), with varying effects on neuronal activity and signaling.

Clinical relevance is broad. Parkinson's disease results from loss of nigrostriatal dopamine, treated with L-DOPA or dopamine agonists, often combined with MAO-B or COMT inhibitors. Schizophrenia is associated with dysregulated dopamine signaling, particularly in mesolimbic pathways, and is treated with D2 receptor antagonists. Dopamine is also implicated in addiction, restless legs syndrome, and attention-related disorders, making it a major focus of neuroscience and pharmacology research.